This study aimed to investigate pembrolizumab (Keytruda) before and after surgery in patients with early triple-negative breast cancer (TNBC). 

This study concluded that the addition of pembrolizumab to chemotherapy before surgery and after surgery for TNBC improved the survival without complications from TNBC in these patients. 

This study evaluated the long-term effectiveness and safety of isatuximab (Sarclisa) in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (Decadron) (Pd) in previously treated patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that isatuximab plus Pd combination significantly improved the overall survival compared to Pd alone in these patients.  

The study investigated the effects of vitamin D (Vit D) supplementation in patients with early breast cancer receiving doxorubicin (DOX; Adriamycin)-based chemotherapy. The results showed that patients taking DOX plus Vit D had improved heart-related blood markers.

The review investigated the effects of neoadjuvant chemo-hormonal therapy (NCHT; chemotherapy and hormonal therapy before surgery) in patients with prostate cancer (PCa). The results showed that compared to patients who received prostate surgery alone, NCHT before prostate surgery improved the oncological outcomes of these patients.  

The study aimed to evaluate the safety and effectiveness of an immunomodulatory IDO/PD-L1 targeting peptide vaccine (IO102/IO103) combined with nivolumab (Opdivo) in patients with metastatic melanoma (MM). The study concluded that the IO102/IO103 vaccine combined with nivolumab is safe and effective in these patients.

This study identified predictors of disease flare in patients with early, active rheumatoid arthritis (RA) that had stopped methotrexate (MTX; Otrexup) and/or abatacept (Orencia) treatment after clinical remission was achieved at 12 months. The data showed that patient function (HAQ-DI) and bone erosion based on magnetic resonance imaging (MRI) scans predicted disease flare at 6 months and 12 months after treatment withdrawal.

The study evaluated the effectiveness and safety outcomes of adding abiraterone acetate (AA; Zytiga) and prednisolone (P; Deltasone) with or without enzalutamide (Xtandi) to androgen-deprivation therapy (ADT) in patients with high-risk non-metastatic prostate cancer (PC). The data showed that AAP added to ADT significantly improved survival without metastasis compared to ADT alone in these patients.

This study evaluated the benefits of a more versus a less intensive blood pressure (BP) lowering treatment strategy in patients with hypertension (high blood pressure). The data showed that a more intensive BP lowering treatment strategy significantly reduced the risks of stroke, heart failure, heart attacks, and cardiovascular death compared to a less intensive BP-lowering treatment strategy in these patients.

This study evaluated the effectiveness of trimetazidine (Vastarel) versus other anti-anginal drugs for the treatment of patients with ischemic heart disease (IHD) who are not suitable for revascularization. The data showed that trimetazidine improved walking time and angina attacks in these patients.

This study evaluated the long-term effectiveness and safety of device-aided therapies (DATs) for the treatment of real-world patients with advanced Parkinson’s disease (PD). The data showed that in the long-term, DATs are well maintained among these patients.